CBS 2019
CBSMD教育中心
中 文

Cardio-Oncology

Abstract

Recommended Article

Lack of Association Between Heart Failure and Incident Cancer Cardiovascular Toxicity in Cancer Survivors: Current Guidelines and Future Directions Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1 Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2

Original Research2021 Mar 22.

JOURNAL:J Proteome Res. Article Link

Metabolic Interactions and Differences between Coronary Heart Disease and Diabetes Mellitus: A Pilot Study on Biomarker Determination and Pathogenesis

WP Liu, PF Guo, T Dai Keywords: diabetes coronary heart disease metabolomics metabolism

ABSTRACT

Comprehensive understanding of plasma metabotype of diabetes mellitus (DM), coronary heart disease (CHD), and especially diabetes mellitus with coronary heart disease (CHDDM) is still lacking. In this work, the plasma metabolic differences and links of DM, CHD, and CHDDM patients were investigated by the strategy of comparative metabolomics based on 1H NMR spectroscopy combined with network analysis for revealing their metabolic differences. A total of 17 metabolites are related to three diseases, among which valine, alanine, leucine, isoleucine, and N-acetyl-glycoprotein are positively correlated with CHD and CHDDM (odds ratios (OR) > 1). The trimethylamine oxide, glycerol, lactose, indoleacetate, and scyllo-inositol are closely related to the development of DM to CHDDM (OR > 1), and indoleactate (OR: 1.06, 95% confidence interval (CI): 1.01–1.12) and lactose (OR: 2.46, 95% CI: 1.67–3.25) are particularly prominent in CHDDM. We identified three multi-biomarkers types that were significantly associated with glycosylated hemoglobin (HbA1C) at baseline. All diseases demonstrated dysregulated glycolysis/gluconeogenesis and amino acid biosynthesis pathway. In addition, enrichment in tryptophan metabolism observed in CHDDM, enrichment in inositol phosphate metabolism observed in DM, and the metabolites related to microbiota metabolism were dysregulated in both DM and CHDDM. The comparative metabolomics strategy of multi-diseases offers a new perspective in disease-specific markers and pathogenic pathways.